Safety and Efficacy of Exosomes Overexpressing CD24 in Two Doses for Patients With Moderate or Severe COVID-19
Status:
Recruiting
Trial end date:
2021-09-01
Target enrollment:
Participant gender:
Summary
This is a phase II randomized, single-blind dose study to evaluate the safety and efficacy of
exosomes overexpressing CD24 of two doses, Dose 1 - 10^9 exosome particles (per dose) versus
Dose 2 - 10^10 exosome particles (per dose), to prevent clinical deterioration in patients
with Moderate or Severe COVID-19 infection.